EU Panel Recommends AstraZeneca's Enhertu for Early Breast Cancer

The EMA's CHMP recommended approval of Enhertu as adjuvant monotherapy for HER2-positive breast cancer with residual disease post-neoadjuvant therapy. This expands the drug's label to earlier-stage disease, potentially broadening its patient population. Approval is likely but not final; commercial impact depends on pricing and reimbursement.